COMMUNIQUÉS West-GlobeNewswire

vTv Therapeutics Announces First Participant Randomized in Phase 2a Pilot Study Evaluating Cadisegliatin in Individuals with Type 1 Diabetes (T1D) Using Hybrid Closed-Loop (HCL) Insulin Delivery Systems
27/10/2026
Phase 2a pilot study aims to inform the design and conduct of future Phase 3 research in this population Cadisegliatin is a potential first-in-class oral therapy being evaluated as an adjunct to insulin for the [...]
Stryker to participate in the 2026 Jefferies Global Healthcare Conference
27/10/2026
Portage, Michigan, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2026 Jefferies Global Healthcare Conference on Tuesday, November 17, 2026 , at the Waldorf Hilton and ME Hotel in London. [...]
Enlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal
27/10/2026
Nes-Ziona, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced receipt of a delisting [...]
Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026
27/10/2026
WILMINGTON, Del., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti- [...]
Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution
27/10/2026
Board appointments align with successful transition to late-stage clinical Company developing pemvidutide as a differentiated liver franchise with multiple potential indications As part of this transition, John M. Gill [...]
AssistRx Named a Central Florida Top Workplace for Sixth Consecutive Year
27/10/2026
Employee feedback-based recognition highlights AssistRx’s focus on growth, inclusion and wellness ORLANDO, Fla., Oct. 27, 2026 (GLOBE NEWSWIRE) -- AssistRx , the advanced therapy initiation and patient solutions [...]
Legend Biotech to Host Investor Conference Call on Third Quarter 2026 Results
27/10/2026
BRIDGEWATER N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 a.m. ET on Tuesday, [...]
Madrigal to Present Multiple Abstracts at AASLD's The Liver Meeting 2026, Including New Real-World Evidence Reinforcing Rezdiffra as a Foundational Therapy for MASH
27/10/2026
Rezdiffra ® (resmetirom) to be featured in more abstracts than any other approved or investigational MASH therapy Real-world evidence abstracts examine Rezdiffra effectiveness, tolerability and treatment persistence in [...]
Calidi Biotherapeutics Presented New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026, Including Highlighting the Potential of its RedTail Gene Medicine Platform to Turn Tumors into Localized TCE Biofactories
27/10/2026
Single-dose CLD-401 induced tumor regression and complete response in 80% of mice in EMT6 breast tumor model Building on the growing clinical evidence supporting T-cell engagers in solid tumors, data showed the platform [...]
Helus Pharma Announces Co-Founders’ Transition from Executive Leadership as Company Advances Toward Next Stage of Development
27/10/2026
Co-founders to step down from executive roles and continue to serve on the Board of Directors Helus Pharma board member, Mark Lawson, appointed as new independent Chair of the Board of Directors, effective immediately [...]
Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline
27/10/2026
BXCL501, a dexmedetomidine sublingual film, is under FDA review for first-ever at-home use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults Acquisition adds [...]
Actuate Therapeutics Announces Pricing of $11.0 Million Underwritten Public Offering
27/10/2026
CHICAGO and FORT WORTH, Texas, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapies [...]
CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union
27/10/2026
Approval under the EU Clinical Trials Regulation builds on CAMP4’s recent clearances in the United Kingdom, Australia, and Argentina to initiate the Company’s global Phase 1/2 trial of CMP-002 Company on track to [...]
Voyager’s Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer’s Disease to Be Featured in Poster Presentations at CTAD 2026
27/10/2026
LEXINGTON, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced two poster [...]
BillionToOne to Participate in Two Upcoming Investor Conferences
27/10/2026
MENLO PARK, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, [...]
Candel Therapeutics to Present at November Investor Conferences
27/10/2026
NEEDHAM, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve [...]
Human Appeal’s Winter Comedy Tour returns for the 12th year running in aid of orphaned children
27/10/2026
Guz Khan, Tez Ilyas, Kae Kurd, Aatif Nawaz, Prince Abdi, Ali Official, Smash Bengali, Riaad Moosa, and Mic Diesel join this year’s UK tour in support of orphan sponsorship programmes worldwide MANCHESTER, United Kingdom [...]
60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients
27/10/2026
All five completed patients (100%) reported much or very much improved clinical outcomes and tested negative for Babesia on conventional PCR tests Four of five completed patients (80%) were negative on highly sensitive [...]
Polyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker
27/10/2026
All 120 planned participants randomized across five clinical sites in the United States Raanana, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a clinical-stage [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum